AI illustration · not actual product photoDetails from the source.
Source-listed CJC-1295 Whitout DAC (SKU CND10): 10mg*10vials. PriceList(1).pdf lists 140 per 10 vials but does not specify currency; the website displays $140 per 10 vials in USD per owner instruction. The source row does not establish the supplier-specific item's identity, lot quality, or approval.
- Catalogue code
- CND10
- Source specification
- 10mg*10vials
- Source document
- PriceList(1).pdf, page 2
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
The source label is exactly “CJC-1295 Whitout DAC” (spelling preserved). Catalogue variants from PriceList(1).pdf p. 2: CND2 — *10vials, 38 per 10 vials; CND5 — *10vials, 76 per 10 vials; CND10 — *10vials, 140 per 10 vials. Currency is not stated. The listing presents it as a peptide and purports to identify a no-DAC form, but does not establish the vial’s actual chemical identity, sequence, salt, or even contents; do not equate it with any specific published peptide based on this alias alone.
Biological mechanism
CJC-1295 in published work is described as a synthetic growth-hormone-releasing-hormone (GHRH) analogue. GHRH receptor activation in pituitary somatotroph cells stimulates GH synthesis and release; GH can stimulate IGF-I production. FDA describes human-study material as DAC-modified CJC-1295 (with some form details unspecified), and the albumin-binding long-acting design cannot be attributed to a product labeled “Whitout DAC.” This is a class-level expected mechanism, not verified for this vial.
Research focus
Research has focused on short-term GH/IGF-I pharmacology in healthy adults and an investigational Phase 2 study in HIV-associated visceral obesity. Separately, DAC-modified material was studied in GHRH-deficient mice. The animal finding is preclinical and does not establish human benefit or identify this no-DAC catalogue item.
Potential applications in the evidence
Only investigational questions are supported: modulation of GH/IGF-I biomarkers and study in HIV-associated visceral obesity. These studies do not establish a clinical application or benefit. No therapeutic use should be inferred for this specific vial.
Human evidence
Two short randomized, placebo-controlled studies in healthy adults aged 21–61 reported increased GH and IGF-I concentrations after long-acting CJC-1295; no serious adverse reactions were reported in those studies. FDA identifies the human-study material as CJC-1295 DAC, with some form details unspecified. The studies measured hormone levels, not clinical outcomes, and do not establish long-term safety or equivalence to this label. ClinicalTrials.gov lists a Phase 2 study in HIV-associated visceral obesity as terminated, with 120 enrolled and no results posted. FDA briefing materials describe a participant’s fatal myocardial infarction after an 11th weekly dose; the attending physician attributed it to previously asymptomatic coronary artery disease with plaque rupture, so the report is a safety signal but does not establish causation.
Known and potential effects
FDA materials describe limited clinical reports of injection-site reactions, systemic vasodilatory reactions, headache, nausea, abdominal pain, diarrhea, transient involuntary leg-muscle contractions, some loss of coordination, transient dizziness, hypotension, and increased heart rate. FDA has also identified serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reaction. These reports do not quantify risks for this exact vial. FDA notes potential risks associated with elevated GH/IGF-I, including glucose intolerance/diabetes, fluid retention, intracranial hypertension, neoplasm risk, and pancreatitis; these are potential axis-related risks, not established rates for this item.
Safety and contraindications
FDA identifies potential immunogenicity and peptide-related impurity/API-characterization concerns for compounded drugs containing CJC-1295, alongside limited clinical safety data. This does not establish that this catalogue item is compounded. No vial-specific contraindications can be verified without a verified composition and approved product labeling. The short biomarker studies cannot settle risks from long-term exposure, and reported cardiovascular/vasodilatory events warrant cautious, non-promotional wording without causal overstatement.
U.S. FDA / regulatory status
No FDA approval for the catalogue-named product or exact vial/formulation was verified in the FDA sources reviewed. FDA lists CJC-1295 among nominated-but-withdrawn bulk drug substances and describes safety concerns; nomination or withdrawal in the compounding process is not drug approval. The listing provides no manufacturer, lot, formulation source, jurisdiction, or approval number, so the exact vial’s authorization and provenance cannot be verified. Do not imply that approval of any distinct active ingredient or branded formulation would transfer to this supplier-specific vial. The available information also does not establish that the item is compounded or research-only.
Evidence limitations
The main published controlled human evidence is short-term, limited in scale, and focused on hormone biomarkers; it concerns long-acting DAC material rather than a chemically authenticated no-DAC catalogue item. The Phase 2 registry has no results posted. FDA notes limited clinical safety data and concerns about characterization and immunogenicity for compounded material. No evidence reviewed verifies the identity, quality, pharmacology, safety, or regulatory status of the contents of CND2, CND5, or CND10. Animal findings are not human evidence.
Supporting sources
- Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults PubMed / Journal of Clinical Endocrinology & Metabolism · Peer-reviewed randomized controlled human study abstract. Supports: Short-term human GH/IGF-I biomarker findings, study design, and absence of serious adverse reactions in the reported trials; the paper describes long-acting CJC-1295.
- Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks U.S. Food and Drug Administration · Regulatory safety webpage. Supports: FDA-identified CJC-1295 adverse events and immunogenicity/peptide-impurity/API-characterization concerns; lists CJC-1295 in nominated-but-withdrawn substances.
- Pharmacy Compounding Advisory Committee briefing materials U.S. Food and Drug Administration · Regulatory advisory-committee briefing document. Supports: FDA review of clinical safety limitations, DAC study-form ambiguity, reported adverse events, the Phase 2 fatal event context, and potential GH/IGF-I-related risks.
- A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity ClinicalTrials.gov / U.S. National Library of Medicine · Clinical trial registry record. Supports: Phase 2 study population/objective, terminated status, enrollment, and absence of posted results.
- Growth hormone-releasing hormone receptor and signaling review PubMed Central / National Library of Medicine · Peer-reviewed review. Supports: General GHRH-receptor/pituitary GH mechanism and downstream GH-to-IGF-I physiology; not identity confirmation for the vial.
- Once-daily administration of CJC-1295 in growth-hormone-releasing-hormone-deficient mice American Physiological Society, American Journal of Physiology-Endocrinology and Metabolism · Peer-reviewed animal study. Supports: Clearly separated preclinical mouse findings and description of the studied albumin-binding DAC form.